Talk:Jeffrey Leiden

This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Biography This article is within the scope of WikiProject Biography, a collaborative effort to create, develop and organize Wikipedia's articles about people. All interested editors are invited to join the project and contribute to the discussion. For instructions on how to use this banner, please refer to the documentation.BiographyWikipedia:WikiProject BiographyTemplate:WikiProject Biographybiography articles

The WP:COIRESPONSE . JohnDatVertex (talk · contribs) has been paid by Vertex Pharmaceuticals on behalf of Jeffrey Leiden.

This edit request by an editor with a conflict of interest has now been answered.

Hi. I am John and I would like to request some updates to Jeffrey Leiden's article.

• Please add the following sentence as a new paragraph in the correct chronological order in the Vertex section, after the sentence that begins "In 2015 Vertex shareholders..." "The 2019 acquisition of Semma Therapeutics led to VX-880, the first potentially curative stem cell-based therapy for patients with type 1 diabetes.^[1][2]

• At the end of the sentence that begins "On October 24, 2019, Vertex reached..." please remove Scotland and Spain and replace with Ireland^[3] and [[France]^[4], among others.

• Also in the Vertex section, please add the following as a new paragraph below the sentence that begins "On October 24, 2019, Vertex reached an agreement..." "While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020.^[5][6]

• In the last paragraph of the Vertex section, please change April 2023 to April 2024.^[7]

Thank you for your help, JohnDatVertex (talk) 17:43, 1 April 2022 (UTC)[reply]

Y Partially done, as the sources provided for #1 said no such thing, and I'm not sure about the reliability of #2's. PK650 (talk) 07:45, 3 April 2022 (UTC)[reply]

I am marking this request as answered, per the above. Z1720 (talk) 14:36, 5 April 2022 (UTC)[reply]

Hi PK650. Thanks for helping out with the above edits. I have re-written the sentence for the first edit that you declined above in a way that more precisely reflects the sources supplied. Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..." "Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880. ^[1][2]"

Thanks so much. JohnDatVertex (talk) 13:10, 16 May 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hi. This is John again. Please update the Boards and awards section with the following sentence: In May 2022 Leiden joined the Board of Directors of Odyssey Therapeutics. ^[1]

 Done

I am pinging PK650 who has helped on this page in the past. Thanks so much. JohnDatVertex (talk) 15:17, 19 May 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hello. Please remove the mention of Tmunity in the second paragraph of the Boards and awards section. Leiden no longer sits on that board. This link shows he is no longer on the board of Tmunity I am pinging Iztwoz who helped with my last edit request. Thanks so much. JohnDatVertex (talk) 12:32, 13 June 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Thanks Iztwoz for implementing my edit request. I have an additional board membership to be added to the "Boards and awards" section as follows: "Leiden is a member of the MIT Presidential CEO Advisory Board." The source is https://www.dropbox.com/s/6nfjmjqb98o9p4k/2022%20MIT%20CEO%20AB%20BRIEFING.pdf?dl=0 on page 21.

I would also appreciate if you could take a look at Talk:Reshma Kewalramani and implement those simple, straightforward edits that are requested there. Thanks again. JohnDatVertex (talk) 13:24, 21 June 2022 (UTC)[reply]

The board membership was resolved below. -Kj cheetham (talk) 17:34, 7 September 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

I have two edits to request, as follows:

• Please add the following sentence to the end of the 'Boards and awards' section:

Leiden is a member of the MIT Presidential CEO Advisory Board.^[1]

• Please add the following as a new paragraph after the sentence that begins "In 2015 Vertex shareholders..."

Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880.^[2][3]

I am pinging Kj cheetham who was helpful with edits for Reshma Kewalramani recently. Thanks so much. JohnDatVertex (talk) 13:39, 31 August 2022 (UTC)[reply]

Hi JohnDatVertex, I've implemented your 2nd point, but do you have a better source for the first point? I'm hestitant to link to something on dropbox. Thanks. -Kj cheetham (talk) 15:21, 1 September 2022 (UTC) P.S. https://www.vrtx.com/our-company/leadership/jeffrey-leiden/ might be sufficient though? -Kj cheetham (talk) 15:29, 1 September 2022 (UTC)[reply]

Hi Kj cheetham. Thanks for implementing the second bullet point above. Sorry that the source for the first bullet point caused you to hesitate about using something on dropbox. I am happy for you to use the Vertex website if you feel that is a better option. Once again, thank you for your work. JohnDatVertex (talk) 17:29, 7 September 2022 (UTC)[reply]

JohnDatVertex  Done -Kj cheetham (talk) 17:33, 7 September 2022 (UTC)[reply]

Thanks Kj cheetham for your fast and helpful edit. JohnDatVertex (talk) 12:41, 9 September 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Thanks again Kj_cheetham for your recent help with this page. I hope you can take a look at the following edits and implement them if you agree they add value to the page.

• For clarity and accuracy, please change the sentence "In May 2022 Leiden joined the Board of Directors of Odyssey Therapeutics" in the "Boards and awards" section to the following:

In May 2022 Leiden was appointed as Chairman of the Board of Odyssey Therapeutics, a company developing novel medicines for cancer and auto-immune disease.^[1]

• Please move the above sentence about Odyssey to the end of the first paragraph in the "Boards and awards" section, directly after "Leiden is also the chairman of Casana, a home health monitoring company. The sentence fits better there since Leiden is the chairman of those boards mentioned in that paragraph.
• Please add the following as a new paragraph in the "Vertex" section below the sentence that begins "On October 24, 2019, Vertex reached an agreement..."

While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020.^[2]

Thanks so much. JohnDatVertex (talk) 18:27, 20 September 2022 (UTC)[reply]

 Done The only thing I've done different is rather than a new paragraph I've added the sentance to the end of an existing one, just to try and avoid too many very short paragraphs. Kj cheetham (talk) 11:19, 2 October 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Once again, I want to express my appreciation to Kj_cheetham for implementing my most recent edit request. Below are a few additional requests:

• Please add the following sentence to the end of the 'Boards and awards' section:

In November 2022 Leiden was named as one of several strategic advisors for the newly launched Life Sciences Private Capital, a private equity division of J.P. Morgan.^[1]

• In the third paragraph of the 'Boards and awards' section please replace this sentence:

Leiden was also named one of Boston Business Journal’s Power 50 in 2018.

With this sentence instead:

Leiden was also named one of Boston Business Journal’s Power 50 for several years, including most recently in 2022.^[2]

Thanks again for all your help. JohnDatVertex (talk) 14:52, 28 November 2022 (UTC)[reply]

Hi Kj cheetham. This is a gentle nudge in the hope that you have the time to make the simple edits as outlined above. Thanks again for all your past and future help. JohnDatVertex (talk) 13:58, 5 December 2022 (UTC)[reply]

 Done Kj cheetham (talk) 12:06, 8 December 2022 (UTC)[reply]

Thanks again Kj cheetham for all your help. JohnDatVertex (talk) 15:21, 15 December 2022 (UTC)[reply]

This edit request by an editor with a conflict of interest has now been answered.

Hi again. The Boards and awards section needs another update. Please change the sentence "He is also chairman of the board of the Massachusetts Competitive Partnership" to the following:

He is a director of the Massachusetts Competitive Partnership (MACP) and previously served as chair from January 2020 to December 2022.^[1][2]

Thanks so much for your help in the past, Kj_cheetham. I am hoping you can help out again with this edit request. JohnDatVertex (talk) 15:36, 21 February 2023 (UTC)[reply]

This new information has been added to the awards section and this edit request has been answered. Go4thProsper (talk) 18:40, 4 March 2023 (UTC)[reply]

The user below has a request that an edit be made to Jeffrey Leiden. That user has an the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies.

Hi. Please remove the following recently added paragraphs from the Vertex section of the Leiden Wikipedia article. The added content violates WP:COATRACK: it has little or nothing to do with Jeffrey Leiden, and adds details that are not relevant for the reader to get a good understanding of Leiden's relationship to Vertex.

Criticism of Vertex pricing structures for Orkambi, a groundbreaking cystic fibrosis drug costing in the region of US$135,000 to US$270,000[23] per patient per year depending on the patient's country, has resulting in campaigns by concerned parent groups addressed to Leiden.[24][25] Leiden wrote to the UK Prime Minister Theresa May in 2018, suggesting Vertex might consider reducing investment in the UK as a result of the lack of agreement between Vertex and the UK's National Health Service on the pricing of a five-year access agreement for Vertex drugs.[26]

However in November 2023 the National Institute for Health and Care Excellence (NICE) recommended that three Vertex drugs, Kaftrio, Orkambi and Symkev were above the acceptable range of NHS resources in terms of cost effectiveness, despite positive outcomes for Cystic Fibrosis patients.[32]

Pinging Kj cheetham who has helped here in the past. Thanks, JohnDatVertex (talk) 14:59, 13 March 2024 (UTC)[reply]